drugset / Trial / NCT00145301

52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine

NCT00145301

Phase 3 Completed 3036 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial will compare the retention on treatment (based on the rate of patients staying on treatment for 1 year) of patients suffering from primary osteoarthritis using two different doses of lumiracoxib (100 mg od or 100 mg bid) or using celecoxib (200 mg od)

Timeline

Start
2004-09
Primary completion
2005-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumiracoxib Small molecule 100 mg

Indications